Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
A phase 2 trial of Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.
Overview
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI is a phase 2 interventional study registered as NCT07181499 by Betta Pharmaceuticals Co., Ltd., with 28 participants planned, started 2025-09 and due to reach its primary completion in 2028-11. Interventions recorded: Befotertinib and Pemetrexed + Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.